Atrial Flutter Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The atrial flutter market reached a value of USD 20.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 32.6 Billion by 2036, exhibiting a growth rate (CAGR) of 4.20% during 2026-2036.

The atrial flutter market has been comprehensively analyzed in IMARC's new report titled "Atrial Flutter Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook". Atrial flutter (AFL) refers to a type of abnormal heart rhythm or arrhythmia that occurs when the upper chambers of the heart beat too fast. It is characterized by a rapid and regular rhythm that generally ranges between 240-360 beats per minute. Atrial flutter is classified as typical or atypical (non-typical) depending on the location of the short circuit — the pathway that allows the electrical signal to move too fast around the heart. Some of the common symptoms of the ailment include palpitations, a fluttering sensation in the chest, shortness of breath, chest discomfort, dizziness, fainting, etc. In few cases, however, atrial flutter may not cause any symptoms at all. It can be diagnosed by conducting several diagnostic tests, such as echocardiograms, Holter monitors, electrophysiological studies, etc. The main treatment options for the ailment include medication, catheter ablation, and surgery. Early diagnosis and treatment of atrial flutter can help prevent serious complications such as stroke and heart failure.

To get more information on this market, Request Sample

The rising incidences of structural heart diseases and coronary artery ailments are primarily augmenting the global atrial flutter market. In addition to this, the increasing prevalence of associated risk factors, including genetic conditions like familial atrial fibrillation and familial dilated cardiomyopathy, high blood pressure, thyroid disorders, etc., is further bolstering the market growth. Moreover, the expanding geriatric population, who are more susceptible to developing cardiovascular diseases, is also creating a positive outlook for the market. Apart from this, the widespread adoption of anti-arrhythmic drugs, such as beta-blockers, calcium channel blockers, amiodarone, etc., that aid in slowing the heart rate and controlling the symptoms of atrial flutter is further propelling the global market. Additionally, the emerging popularity of catheter ablation, which utilizes radiofrequency energy to destroy small areas of heart tissue causing abnormal electrical signals that further lead to atrial flutter, is also bolstering the market growth. Besides this, the increasing utilization of pacemakers or implantable cardioverter-defibrillators (ICDs) for regulating the heart's rhythm and preventing atrial flutter from recurring is acting as another significant growth-inducing factor. Furthermore, several technological advancements, including the introduction of cardiac mapping devices for identifying and localizing complex arrhythmias, are also expected to drive the atrial flutter market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the atrial flutter market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for atrial flutter and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atrial flutter market in any manner.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the atrial flutter market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the atrial flutter market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current atrial flutter marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the atrial flutter market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the atrial flutter market across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the atrial flutter market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of atrial flutter across the seven major markets?
• What is the number of prevalent cases (2020-2036) of atrial flutter by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of atrial flutter by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of atrial flutter by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with atrial flutter across the seven major markets?
• What is the size of the atrial flutter patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of atrial flutter?
• What will be the growth rate of patients across the seven major markets?
   

Atrial Flutter: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for atrial flutter drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atrial flutter market?
• What are the key regulatory events related to the atrial flutter market?
• What is the structure of clinical trial landscape by status related to the atrial flutter market?
• What is the structure of clinical trial landscape by phase related to the atrial flutter market?
• What is the structure of clinical trial landscape by route of administration related to the atrial flutter market?